IMD 2560

Drug Profile

IMD 2560

Alternative Names: IMD-2560

Latest Information Update: 28 May 2013

Price : $50

At a glance

  • Originator Institute of Medicinal Molecular Design
  • Class Anti-inflammatories
  • Mechanism of Action I-kappa B kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Osteoporosis; Rheumatoid arthritis

Most Recent Events

  • 28 May 2013 IMD 2560 is available for licensing as of 28 May 2013. http://www.immd.co.jp
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top